I find the use of AI in this 'Compare and contrast' method is particularly useful and in particular saves so much time similarly, being able to just put in a link to an article and for example ask if DCVax is referenced, again the time it saves having to read through it all is truly impressive.
Another very useful example of how it can really help with research is this example where I asked it to simply analyse Marnix Bosch's presentation on DCVax®-L:
Mechanism of Action, Immunological Effects, and Clinical Trial
External Controls Methodology
• The presentation explains the mechanism of action of DCVax-L, a personalized dendritic cell vaccine for glioblastoma and other solid tumors. DCVax-L is made from the patient’s own dendritic cells (DCs), which are the master cells of the immune system, and the patient’s own tumor cell lysate, which contains a broad spectrum of tumor antigens. DCVax-L is intended to activate the patient’s T cells to recognize and attack the tumor cells, while avoiding immune suppression by the tumor microenvironment1.
• The presentation shows the immune monitoring data from the phase 3 trial of DCVax-L for newly diagnosed glioblastoma (nGBM). The data demonstrate that DCVax-L induced a robust and durable immune response in the patients, as measured by the activation and expansion of T cells, the production of cytokines, and the infiltration of T cells into the tumor tissue. The immune response was also associated with the survival outcomes, as the patients who had higher immune activation had longer overall survival1.
• The presentation also describes the external controls methodology used in the phase 3 trial of DCVax-L for nGBM. The trial used external control patients (ECPs) as a comparator group, instead of a placebo group, due to ethical and practical challenges. The ECPs were derived from five other contemporaneous randomized clinical trials that used the same standard of care (SOC) as the DCVax-L trial. The ECPs were matched to the DCVax-L patients based on multiple prognostic factors, such as age, performance status, extent of resection, MGMT status, and IDH status. The presentation shows that the DCVax-L patients had significantly longer overall survival than the ECPs, with a median survival of 23.1 months vs 15.2 months, and a 3-year survival rate of 28.4% vs 11.3%1.
• The presentation also reports the observations from the compassionate use program of DCVax-L for recurrent glioblastoma (rGBM) and other solid tumors. The program enrolled patients who had exhausted all other treatment options and had a life expectancy of less than 6 months. The presentation shows that some of the patients who received DCVax-L had remarkable responses, such as complete or partial tumor regression, prolonged survival, and improved quality of life.
• The presentation concludes that DCVax-L is a promising immunotherapy for glioblastoma and other solid tumors, and that it has the potential to improve the survival and quality of life of patients who have limited treatment options. The presentation also states that the company is planning to pursue regulatory approvals for DCVax-L in the US and Europe, and to expand the clinical development of DCVax-L to other indications, such as ovarian cancer, prostate cancer, and colorectal cancer
Bullish
News 
Market Data 
Discover 
